blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4010329

EP4010329 - DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.04.2024
Database last updated on 22.08.2024
FormerThe patent has been granted
Status updated on  05.05.2023
FormerGrant of patent is intended
Status updated on  14.12.2022
FormerRequest for examination was made
Status updated on  13.05.2022
FormerThe international publication has been made
Status updated on  19.02.2021
Formerunknown
Status updated on  20.08.2020
Most recent event   Tooltip12.04.2024No opposition filed within time limitpublished on 15.05.2024  [2024/20]
Applicant(s)For all designated states
Artios Pharma Limited
Babraham Hall
Babraham Research Campus
Cambridge CB22 3AT / GB
[2022/24]
Inventor(s)01 / BLENCOWE, Peter
c/o Artios Pharma Limited Babraham Hall Babraham
Research Campus
Cambridge CB22 3AT / GB
02 / CHARLES, Mark
c/o Artios Pharma Limited Babraham Hall Babraham
Research Campus
Cambridge CB22 3AT / GB
03 / EKWURU, Tennyson
c/o Artios Pharma Limited Babraham Hall Babraham
Research Campus
Cambridge CB22 3AT / GB
04 / FINCH, Harry
c/o Artios Pharma Limited Babraham Hall Babraham
Research Campus
Cambridge CB22 3AT / GB
05 / MCCARRON, Hollie
c/o Artios Pharma Limited Babraham Hall Babraham
Research Campus
Cambridge CB22 3AT / GB
06 / HEALD, Robert
c/o Artios Pharma Limited Babraham Hall Babraham
Research Campus
Cambridge CB22 3AT / GB
07 / STOCKLEY, Martin
c/o Artios Pharma Limited Babraham Hall Babraham
Research Campus
Cambridge CB22 3AT / GB
 [2022/24]
Representative(s)Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
[N/P]
Former [2022/24]Gibson, Mark
Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
Application number, filing date20754011.310.08.2020
[2022/24]
WO2020GB51901
Priority number, dateWO2019GB5224009.08.2019         Original published format: PCT/GB2019/052240
GB2019001786306.12.2019         Original published format: GB 201917863
[2022/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021028670
Date:18.02.2021
Language:EN
[2021/07]
Type: A1 Application with search report 
No.:EP4010329
Date:15.06.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 18.02.2021 takes the place of the publication of the European patent application.
[2022/24]
Type: B1 Patent specification 
No.:EP4010329
Date:07.06.2023
Language:EN
[2023/23]
Type: B9 Corrected patent specification 
No.:EP4010329
Date:04.10.2023
[2023/40]
Search report(s)International search report - published on:EP18.02.2021
ClassificationIPC:C07D401/04, A61K31/4439, A61P35/00
[2022/24]
CPC:
C07D401/04 (EP,IL,KR,US); A61K31/4439 (KR,US); A61K45/06 (US);
A61P35/00 (EP,IL,KR); C07B59/002 (KR); C07B2200/05 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/24]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:DEUTERIERTE VERBINDUNGEN ZUR VERWENDUNG BEI DER BEHANDLUNG VON KREBS[2022/24]
English:DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER[2022/24]
French:COMPOSÉS DEUTÉRÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER[2022/24]
Entry into regional phase04.03.2022National basic fee paid 
04.03.2022Designation fee(s) paid 
04.03.2022Examination fee paid 
Examination procedure04.03.2022Examination requested  [2022/24]
04.03.2022Date on which the examining division has become responsible
21.09.2022Amendment by applicant (claims and/or description)
15.12.2022Communication of intention to grant the patent
12.04.2023Fee for grant paid
12.04.2023Fee for publishing/printing paid
12.04.2023Receipt of the translation of the claim(s)
Opposition(s)08.03.2024No opposition filed within time limit [2024/20]
Fees paidRenewal fee
16.08.2022Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2013107291  (AGIOS PHARMACEUTICALS INC [US], et al) [A] 1-10 * the whole document *;
 [A]WO2013107405  (AGIOS PHARMACEUTICALS INC [US], et al) [A] 1-10 * the whole document *;
 [A]WO2015010297  (AGIOS PHARMACEUTICALS INC [US], et al) [A] 1-10 * the whole document *;
 [A]WO2018001332  (SHANGHAI HAIHE PHARMACEUTICAL CO LTD [CN], et al) [A] 1-10 * the whole document *;
 [A]  - JANETA POPOVICI-MULLER ET AL, "Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers", ACS MEDICINAL CHEMISTRY LETTERS, US, (20180412), vol. 9, no. 4, doi:10.1021/acsmedchemlett.7b00421, ISSN 1948-5875, pages 300 - 305, XP055630303 [A] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1021/acsmedchemlett.7b00421
by applicantWO2017062754
    - TRUONG et al., PNAS, (20130000), vol. 110, no. 19, pages 7720 - 7725
    - "UniProtKB", Database accession no. 075417
    - KENT et al., Nature Structural & Molecular Biology, (20150000), vol. 22, no. 3, pages 230 - 237
    - MATEOS-GOMEZ et al., Nature, (20150000), vol. 518, no. 7538, pages 258 - 262
    - WOODDOUBLIE, DNA Repair, (20160000), vol. 44, pages 22 - 32
    - HIGGINS et al., Oncotarget, (20100000), vol. 1, pages 175 - 184
    - LEMEE et al., PNAS, (20100000), vol. 107, no. 30, pages 13390 - 13395
    - KAWAMURA et al., International Journal of Cancer, (20040000), vol. 109, no. 1, pages 9 - 16
    - EMAMI S et al., Biolmpacts, (20180000), vol. 8, no. 4, pages 305 - 320
    - W. DEADY, Syn. Commun., (19770000), vol. 7, pages 509 - 514
    - Drugs of Today, (19830000), vol. 19, no. 9, pages 499 - 538
    - H. BUNDGAARD, Topics in Chemistry, Elsevier, (19850000), pages 306 - 316
    - H. BUNDGAARD, Design of Prodrugs
    - T. GREENP. WUTS, Handbook of OrganoPalladium Chemistry for Organic Synthesis, John Wiley and Sons, (20070000), vol. 1
    - R. G. STRICKLY, "Solubilizing Excipients in oral and injectable formulations", Pharmaceutical Research, (20040000), vol. 21, no. 2, pages 201 - 230
    - J. Control. Release, (20030000), vol. 91, no. 1-2, pages 167 - 172
    - SINHA et al., Mol. Cancer Ther., (20060801), vol. 5, page 1909
    - CHIOURIEGELMAN, J. Pharm. Sci., (19710000), vol. 60, pages 1281 - 1300
    - CHOU TCTALALAY P, "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors", Adv Enzyme Regulat, (19840000), vol. 22, doi:10.1016/0065-2571(84)90007-4, pages 27 - 55, XP023796270

DOI:   http://dx.doi.org/10.1016/0065-2571(84)90007-4
    - CHEMICAL ABSTRACTS, Database accession no. 22123-14-4
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.